Cargando…
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry
AIMS: Failure to prescribe key medicines at evidence‐based doses is associated with increased mortality and hospitalization for patients with Heart Failure with reduced Ejection Fraction (HFrEF). We assessed titration patterns of guideline‐recommended HFrEF medicines internationally and explored ass...
Autores principales: | Cowie, Martin R., Schöpe, Jakob, Wagenpfeil, Stefan, Tavazzi, Luigi, Böhm, Michael, Ponikowski, Piotr, Anker, Stefan D., Filippatos, Gerasimos S., Komajda, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006614/ https://www.ncbi.nlm.nih.gov/pubmed/33569926 http://dx.doi.org/10.1002/ehf2.13237 |
Ejemplares similares
-
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022) -
Totality of evidence in trials of sodium–glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice
por: Butler, Javed, et al.
Publicado: (2020) -
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2023) -
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
por: Butler, Javed, et al.
Publicado: (2021) -
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
por: Butler, Javed, et al.
Publicado: (2021)